Market
How will J&J's stock react to the acquisition announcement by February 13, 2025?
2
Resolution / Starting Odds
J&J stock rises by more than 5% • 25%
J&J stock falls by more than 5% • 25%
J&J stock remains within 5% of current price • 25%
Other • 25%
Stock market data from financial platforms like Bloomberg or Reuters
Story
Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio with Caplyta
Jan 13, 2025, 12:19 PM
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for $14.6 billion in cash, or $132 per share. The deal, announced on the first day of the J.P. Morgan Healthcare Conference, aims to bolster Johnson & Johnson's neuroscience portfolio with Intra-Cellular's Caplyta, a drug approved for treating schizophrenia and bipolar depression. Intra-Cellular recently filed for an expanded approval of Caplyta to treat major depressive disorder, which could significantly increase its market potential. The acquisition also includes ITI-1284, a drug in Phase 2 testing for generalized anxiety disorder and Alzheimer's-related conditions. Johnson & Johnson plans to fund the acquisition through cash on hand and debt, with the deal expected to close later in 2025, subject to regulatory approvals.
View original story
Similar markets
No significant increase • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No change • 25%
Decrease • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
No significant change • 25%
Decrease • 25%
No significant impact • 25%
New competitors emerge • 25%
Competitors lose market share • 25%
Competitors gain market share • 25%
Acquisition delayed • 25%
No official outcome by end of 2025 • 25%
Acquisition completed • 25%
Acquisition abandoned • 25%
Acquisition Completed • 25%
Other Outcomes • 25%
Acquisition Delayed • 25%
Acquisition Abandoned • 25%
Yes • 50%
No • 50%
Outside Top 10 • 25%
Top 3 • 25%
Top 5 • 25%
Top 10 • 25%
AstraZeneca • 25%
Other • 25%
Gilead Sciences • 25%
Biogen • 25%